Luca Franchini

Luca Franchini

Auto-generated profile, based on publicly available information

Luca Franchini

Department of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
LFLuca Franchini
Luca Franchini
JPJoseph Porter
Joseph Porter
JLJohn D. Lueck
John D. Lueck
COCesare Orlandi
Cesare Orlandi
G protein-coupled receptors (GPCRs) are key pharmacological targets, yet many remain underutilized due to unknown activation mechanisms and ligands. Orphan GPCRs, lacking identified natural ligands, are a high priority for research, as identifying their ligands will aid in understanding their functions and potential as drug targets. Most GPCRs, including orphans, couple to Gi/o/z family members, however current assays to detect their activation are limited, hindering ligand identification efforts. We introduce GzESTY, a sensitive, cell-based assay developed in an easily deliverable format designed to study the pharmacology of Gi/o/z-coupled GPCRs and assist in deorphanization. We optimized assay conditions and developed an all-in-one vector employing cloning methods to ensure the correct expression ratio of GzESTY components. GzESTY successfully assessed activation of a library of ligand-activated GPCRs, detecting both full and partial agonism, and responses from endogenous GPCRs. Notably, with GzESTY we established the presence of endogenous ligands for GPR176 and GPR37 in brain extracts, validating its use in deorphanization efforts. This assay enhances the ability to find ligands for orphan GPCRs, expanding the toolkit for GPCR pharmacologists.

29 June 2026 in Communications Biology
Verified
Journal Article
Open access
PDF file
LZLucrezia Zanetti
Lucrezia Zanetti
LFLuca Franchini
Luca Franchini
SSShirsha Saha
Shirsha Saha
YLYini Liao
Yini Liao
BMBrian Muntean
Brian Muntean
COCesare Orlandi
Cesare Orlandi
Dopamine receptors are G protein coupled receptors (GPCRs) that serve as key targets for FDA-approved drugs to treat various neuropsychiatric disorders. Notably, ~11% of all marketed GPCR-targeting drugs act on dopamine receptors. Five GPCRs mediate the effects of endogenous dopamine and compounds used to treat Parkinson’s disease, schizophrenia, and other conditions. However, on-target side effects associated with these medications highlight the need to analyze dopamine receptor signaling to design safer, more effective therapeutics. Here, we characterize the G protein coupling of dopamine D2-like receptors and observe the striking inability of D3R to engage with Gαi proteins while effectively activating Gαo/z subtypes. Applying orthogonal cell-based assays with wild-type G proteins in parental and ΔGαi/o/z cells, we conclusively establish that D3R does not activate Gαi proteins. Further analysis of Gαi2:GαoA and D2R:D3R chimeras reveals that this selective inability is driven by molecular determinants located within the α5 helix of Gαi and ICL2 of D3R. Guided by cryo-EM structures, we model the interface between these regions to clarify the structural basis of selectivity. Finally, treating hippocampal neurons in acute slices with selective agonists and antagonists reveals marked differences in their regulation of endogenous adenylyl cyclase and cAMP, underscoring the neurophysiological significance of our findings.